ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue13,073.2596,473.978--
Cost of Revenue7,419.9884,853.664--
Gross Profit5,653.2711,620.314--
Operating Expenses
Research Development7,526.7849,697.1364,843.1393,924.409
Selling General and Administrative22,819.22417,127.5559,007.2895,891.616
Non Recurring----
Others----
Total Operating Expenses37,765.99631,678.35513,850.4289,816.025
Operating Income or Loss-24,692.737-25,204.377-13,850.428-9,816.025
Income from Continuing Operations
Total Other Income/Expenses Net-1,185.6341,192.36278.431-1,052.523
Earnings Before Interest and Taxes-24,692.737-25,204.377-13,850.428-9,816.025
Interest Expense-231.291-214.396-214.396-371.708
Income Before Tax-25,878.371-24,012.017-13,571.997-10,868.548
Income Tax Expense-339.391-4,574.765--
Minority Interest----
Net Income From Continuing Ops-25,538.98-19,437.252-13,571.997-10,868.548
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-25,538.98-19,437.252-13,571.997-10,868.548
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-25,538.98-20,811.481-13,571.997-10,868.548